arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

Burning Rock Biotech Ltd

BNR
$14.75 ▼ -1.73 (-10.50%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
7 Visible periods
4 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Burning Rock Biotech Ltd faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
15
Returns
34
Financial Health
3
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 7 quarters